SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq:
NUVA), a medical device company focused on developing products for minimally
disruptive surgical treatments for the spine, announced today details relating
to its first quarter 2009 earnings announcement, which will take place on
Wednesday, April 22, 2009 after the close of the market.
NuVasive will hold a conference call on Wednesday, April 22, 2009 at 5:30
p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are
1-877-407-4018 for domestic callers and 1-201-689-8471 for international. A
live webcast of the conference call will be available online from the investor
relations page of the Company's corporate website at www.nuvasive.com.
After the live webcast, the call will remain available on NuVasive's
website, www.nuvasive.com, through May 22, 2009. In addition, a telephonic
replay of the call will be available until May 6, 2009. The replay dial-in
numbers are 1-877-660-6853 for domestic callers and 1-201-612-7415 for
international callers. Please use account number 3055 and conference ID number
320044.
About NuVasive
NuVasive is a medical device company focused on the design, development,
and marketing of products for the surgical treatment of spine disorders. The
Company's product portfolio is focused primarily on the $4.6 billion U.S.
spine implant market. Additionally, the Company has expanded into the $1.5
billion global biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines four categories of
products that collectively minimize soft tissue disruption during spine
surgery with maximum visualization and safe, easy reproducibility for the
surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS significantly
reduces surgery time and returns patients to activities of daily living much
faster than conventional approaches. Having redefined spine surgery with the
MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or
XLIF(R), NuVasive has built an entire spine franchise. With nearly 50
products today spanning lumbar, thoracic and cervical applications, the
Company will continue to expand and evolve its offering predicated on its R&D
focus and dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which, if they do
not materialize or prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties that could
cause actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or clearance
for NuVasive's products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require significant
changes to NuVasive's products or clinical studies; the risk that products may
not perform as intended and may therefore not achieve commercial success; the
risk that competitors may develop superior products or may have a greater
market position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's public
filings with the Securities and Exchange Commission are available at
www.sec.gov. NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date on which
it was made.
Contact:
Kevin C. O'Boyle
EVP & Chief Financial Officer
NuVasive, Inc.
858-909-1998
investorrelations@nuvasive.com
Investors:
Patrick F. Williams
Vice President, Finance & Investor Relations
NuVasive, Inc.
858-638-5511
investorrelations@nuvasive.com
Media:
Jason Rando
The Ruth Group
646-536-7025
jrando@theruthgroup.com
SOURCE NuVasive, Inc.
04/14/2009
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer,
+1-858-909-1998, investorrelations@nuvasive.com, or Patrick F. Williams, Vice
President, Finance & Investor Relations, +1-858-638-5511,
investorrelations@nuvasive.com, both of NuVasive, Inc.; or Jason Rando of The
Ruth Group, +1-646-536-7025, jrando@theruthgroup.com
Web Site: http://www.nuvasive.com